论文部分内容阅读
目的:评价卡维地络治疗慢性顽固性充血性心衰的疗效及安全性。方法:将46例慢性顽固性心力衰竭患者随机分为两组,治疗组24例与对照组22例。46例患者经强化利尿强心治疗症状好转后,对照组继续用洋地黄、利尿剂及ACEI等药物治疗,治疗组在对照组治疗的基础上加用卡维地络2.5~5.0mg,2次/d。比较两组的疗效。结果:两组患者疗效比较差异有统计学意义(P<0.05),治疗组较对照组改善明显。两组均无严重不良反应发生。结论:治疗剂量的卡维地络治疗经强化利尿强心治疗后症状好转的慢性顽固性充血性心衰的疗效显著且安全。
Objective: To evaluate the efficacy and safety of carvedilol in the treatment of chronic intractable congestive heart failure. Methods: Forty-six patients with chronic intractable heart failure were randomly divided into two groups: 24 cases in the treatment group and 22 cases in the control group. Forty-six patients were treated with intensive diuretic cardiomyopathy and the control group continued to receive drugs such as digitalis, diuretics and ACEI. The treatment group was treated with carvedilol 2.5-5.0 mg on the basis of the control group, / d. Compare the curative effect of two groups. Results: There was significant difference between the two groups in the curative effect (P <0.05), and the treatment group improved significantly compared with the control group. No serious adverse reactions occurred in both groups. CONCLUSIONS: Therapeutic doses of carvedilol are significant and safe in the treatment of chronic refractory congestive heart failure with improved symptoms after intensive diuretic cardiomyopathy.